A new analysis of 6,239 adults found semaglutide provided benefits beyond weight loss, including improvements in cardiometabolic health measures. The findings add to evidence that the GLP-1 receptor agonist affects multiple health outcomes. Semaglutide remains one of the most widely prescribed drugs for obesity and type 2 diabetes.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.